.Attribute Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ state-of-the-art breast cancer as well as active or even stable human brain metastases revealed constant intracranial task and systemic effectiveness of T-DXd.